Literature DB >> 30386867

Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?

Hajira Ilyas1, N George Mikhaeel2, Joel T Dunn3, Fareen Rahman2, Henrik Möller4, Daniel Smith2, Sally F Barrington5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30386867     DOI： 10.1007/s00259-018-4200-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

1.  Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?

Authors:  Anne-Ségolène Cottereau; Irene Buvat; Salim Kanoun; Annibale Versari; Olivier Casasnovas; Stephane Chauvie; Jérôme Clerc; Andrea Gallamini; Michel Meignan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-12       Impact factor: 9.236

2.  Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma.

Authors:  Myriam Sasanelli; Michel Meignan; Corinne Haioun; Alina Berriolo-Riedinger; René-Olivier Casasnovas; Alberto Biggi; Andrea Gallamini; Barry A Siegel; Amanda F Cashen; Pierre Véra; Hervé Tilly; Annibale Versari; Emmanuel Itti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-06-06       Impact factor: 9.236

3.  Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.

Authors:  Umberto Vitolo; Marek Trněný; David Belada; John M Burke; Angelo Michele Carella; Neil Chua; Pau Abrisqueta; Judit Demeter; Ian Flinn; Xiaonan Hong; Won Seog Kim; Antonio Pinto; Yuan-Kai Shi; Yoichi Tatsumi; Mikkel Z Oestergaard; Michael Wenger; Günter Fingerle-Rowson; Olivier Catalani; Tina Nielsen; Maurizio Martelli; Laurie H Sehn
Journal:  J Clin Oncol       Date:  2017-08-10       Impact factor: 44.544

4.  Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma.

Authors:  Salim Kanoun; Ilan Tal; Alina Berriolo-Riedinger; Cédric Rossi; Jean-Marc Riedinger; Jean-Marc Vrigneaud; Louis Legrand; Olivier Humbert; Olivier Casasnovas; François Brunotte; Alexandre Cochet
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

5.  Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma.

Authors:  Hajira Ilyas; N George Mikhaeel; Joel T Dunn; Fareen Rahman; Henrik Møller; Daniel Smith; Sally F Barrington
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-19       Impact factor: 9.236
  5 in total
  5 in total

1.  Discovery of Pre-Treatment FDG PET/CT-Derived Radiomics-Based Models for Predicting Outcome in Diffuse Large B-Cell Lymphoma.

Authors:  Russell Frood; Matthew Clark; Cathy Burton; Charalampos Tsoumpas; Alejandro F Frangi; Fergus Gleeson; Chirag Patel; Andrew F Scarsbrook
Journal:  Cancers (Basel)       Date:  2022-03-28       Impact factor: 6.639

2.  Value of Primary Rectal Tumor PET/MRI in the Prediction of Synchronic Metastatic Disease.

Authors:  Marcelo A Queiroz; Cinthia D Ortega; Felipe R Ferreira; Fernanda C Capareli; Sergio C Nahas; Giovanni G Cerri; Carlos A Buchpiguel
Journal:  Mol Imaging Biol       Date:  2021-11-09       Impact factor: 3.488

3.  Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.

Authors:  Paul Blanc-Durand; Simon Jégou; Salim Kanoun; Alina Berriolo-Riedinger; Caroline Bodet-Milin; Françoise Kraeber-Bodéré; Thomas Carlier; Steven Le Gouill; René-Olivier Casasnovas; Michel Meignan; Emmanuel Itti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-24       Impact factor: 9.236

4.  Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.

Authors:  Romain-David Seban; Laura Mezquita; Arnaud Berenbaum; Laurent Dercle; Angela Botticella; Cécile Le Pechoux; Caroline Caramella; Eric Deutsch; Serena Grimaldi; Julien Adam; Samy Ammari; David Planchard; Sophie Leboulleux; Benjamin Besse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-21       Impact factor: 9.236

5.  Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review.

Authors:  R Frood; C Burton; C Tsoumpas; A F Frangi; F Gleeson; C Patel; A Scarsbrook
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-18       Impact factor: 9.236
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.